ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş. Özel Durum Açıklaması (Genel) 19 Ocak 2026

Oncosem provides services to approximately 60,000 patients receiving chemotherapy treatment per month across nearly 40 chemotherapy centers throughout Türkiye, using high-technology systems and equipment that are entirely self-manufactured, with an approximate domestic production rate of 80%.

Within the scope of reimbursement under the Social Security Institution (SGK) Health Implementation Communiqué (SUT), in addition to the 20% increase that came into effect as of 1 January 2026, an additional increase of 54% has been implemented, effective as of 1 February 2026. Accordingly, the SUT unit prices have increased by approximately 85% in total.

With this price update, while maintaining the current service volume, it is expected that the monthly invoicing amount for chemotherapy services, which currently stands at approximately TRY 30–35 million, will increase to the range of TRY 55–65 million. The stated amount range is expressed as an approximation due to monthly fluctuations in the number of patients receiving chemotherapy services.

This increase is expected to result in a direct increase in revenue and profitability at approximately the same rate, without requiring any significant change in operational service volume or cost structure.

Thanks to the SUT price updates, it is anticipated that Oncosem will achieve strong and sustainable growth in revenue and EBITDA levels, enhance its cash generation capacity, and thereby deliver lasting and robust growth in its financial performance.

Respectfully submitted to the public.